HK Stock Market Move | Guangzhou Baiyunshan Pharmaceutical Holdings (00874) rose more than 4% after releasing its performance report, with a net profit of 3.31 billion yuan in the first three quarters of the year. Its subsidiary, Wanglaoji International Can, made its debut in the Middle Eastern market for the first time.

Guangzhou Baiyunshan Pharmaceutical Holdings (00874) rose more than 4% after the performance announcement. As of the time of writing, it had risen by 4.61% to 18.85 Hong Kong dollars, with a turnover of 58.33 million Hong Kong dollars. On the news front, on October 28th, Guangzhou Baiyunshan Pharmaceutical Holdings released its financial results for the first three quarters of 2025. The group achieved operating income of 61.606 billion yuan, a year-on-year increase of 4.31%; net profit attributable to shareholders of the listed company was 3.31 billion yuan, a year-on-year increase of 4.78%; and basic earnings per share were 2.036 yuan. It is worth mentioning that recently, the Fortune Global Forum was held in Riyadh, the capital of Saudi Arabia. Guangzhou Baiyunshan Pharmaceutical Holdings' subsidiary Wanglaoji Health was invited to attend, and during the forum, the launch ceremony of "WALOVI" international canned product in Saudi Arabia was held. Following the release of the "WALOVI" English brand logo in Saudi Arabia in February this year, Wanglaoji international canned product has officially entered the Saudi market for the first time, marking a key step in Wanglaoji's global expansion into the Middle East.